Program

21st International RUNX Conference
Philadelphia, PA, USA
November 12—15, 2017

Program

Smilow Center for Translational Research (SCTR) Commons and Rubenstein Auditorium
3400 Civic Center Boulevard
Philadelphia, PA 19104

Registration and meals, unless otherwise indicated, will be held in SCTR Commons.
All talks will be in Rubenstein Auditorium.
 

Sunday, November 12
13:00-15:00 Registration and coffee (SCTR)
15:00-15:10 Opening Remarks from Nancy A. Speck and Timothy Babich (Rubenstein Auditorium, SCTR)
15:10-16:30

Session 1. RUNX1 and the birth of blood                                                                                                

Chair: Marella de Bruijn

15:10-15:30

Marella de Bruijn (University of Oxford)                                                                                             

Dynamic regulation of Runx1 at the onset of definitive hematopoiesis

15:30-15:50

Erica Bresciani (National Human Genome Research Institute)                                                    

Development of RUNX1-independent hematopoiesis in three zebrafish runx1-KO models

15:50-16:10

Motomi Osato (National University of Singapore)

Enhancer for Runx1, eR1: a powerful tool in stem cell and cancer biology

16:10-16:30

Georges Lacaud (University of Manchester)

Regulation of RUNX1 dosage is crucial for efficient blood formation from hemogenic endothelium

16:30-16:50 Coffee
16:50-17:50

Session 2: RUNX proteins in normal hematopoiesis 

Chair: Ichiro Taniuchi

16:50-17:10

Peter Balogh (University of Virginia)

RUNX3 is required for megakaryocyte-erythroid specification in primary human progenitors

17:10-17:30

Brian Estevez (Children's Hospital of Philadelphia)

TGFBR1 inhibitor RepSox improves defective megakaryocyte maturation and yield in a patient-derived iPSC model of FPD/AML

17:30-17:50

Alan Friedman (Johns Hopkins University)

A Runx1-regulated Cebpa enhancer contributes to B/myeloid development

18:00-19:30 Reception and Dinner (Jordan Medical Education Center, Atrium)
19:40-20:20 Session 2. RUNX proteins in normal hematopoiesis (continued)
19:40-20:00 Ichiro Tanuichi (RIKEN)

Unique roles of the C-terminal end sequences in Runx and Cbfb proteins

20:00-20:20

Ivo Touw (Erasmus University Medical Center)

Combinatorial CSF3R and RUNX1 mutations involved in malignant transformation of Severe Congenital Neutropenia cause a G-CSF-dependent premalignant state in mice

20:20–20:40

Michelle West (University of Sussex)

Differential binding of RUNX proteins in B cells

20:40-21:04

Session 3. Speed talks I

Chair:   Lucio Castilla

20:40-20:44

Erika Mijia Kwon (National Human Genome Research Institute)

Establishment of RUNX1-reporter hiPSC lines to identify compounds that promote hematopoietic differentiation

20:44-20:48

Tomomasa Yokomizo (Kumamoto University)

Spatio-temporal analysis of HSC-producing hematopoietic clusters in the mouse embryo

20:48-20:52

Julia Draper (University of Manchester)

Runx1 isoforms and fetal liver progenitors: enhanced purification aids the study of in utero hematopoietic defects

20:52-20:56

Sara Borst (Children’s Hospital of Philadelphia)

Investigating the mechanism of thrombocytopenia resulting from mono-allelic mutations in ETV6 and RUNX1

20:56-21:00

Jamie Diemer (National Human Genome Research Institute)

Use of single-cell transcriptomics to understand CBFB-MYH11 leukemogenesis

21:00-21:04

Serine Avagyan (Dana Farber Cancer Institute)

Clonal hematopoiesis in models of MDS/AML predisposition in zebrafish

Monday, November 13
8:00-9:00 Breakfast (SCTR Commons)
9:00-9:10 Remarks: Robert Vonderheide (Director, Abramson Cancer Center)
9:10-12:00

Session 4. RUNX proteins in inflammation and leukemia

Chairs: Dong-Er Zhang and Yoshiaki Ito

9:10-9:30

Takashi Ebihara (RIKEN)

Runx/CBFβ restrains constitutive activation of Type II innate lymphoid cells to preserve them from exhaustion in allergic inflammation

9:30-9:50

Dana Bellissimo (University of Pennsylvania)

RUNX1 loss increases inflammatory cytokine production by granulocytes

9:50-10:10

Anna Brown (University of South Australia, Adelaide)

Identification of novel biomarkers, with targeted therapies, in RUNX1 mutated malignancies

10:10-10:30

Dong-Er Zhang (University of California San Diego)

Transcriptional repression of RASSF2 impairs hippo kinase-dependent p53 regulation and tumor suppression in t(8;21) AML

10:30-11:00 Coffee Break (SCTR Commons)
11:00-11:20

Lucio Castilla (University of Massachusetts, Worcester)

CBFβ-SMMHC modulates enhancer chromatin dynamics and maintains MYC activity in inv(16) acute myeloid leukemia

11:20-11:40

Julia Horsfield (University of Otago)

Cohesin mutations in myeloid leukaemia: the RUNX1 connection

11:40-12:00

Yoshiaki Ito (National University of Singapore)

Induction of luminal type breast cancer by knock out of Runx1 or Runx3 in luminal epithelial stem cells

12:00-13:00 Lunch (SCTR Commons)
13:10 – 16:00

Session 5. Familial Platelet Disorder with Predisposition for AML (RUNX1 Research Program Investigators)

Chairs: Paul Liu and Nancy Speck

13:10-13:30

Ravi Majeti (Stanford University)

Characterization of pre-leukemic HSPCs with engineered FPD/AML RUNX1 mutations 

13:30-13:50

Alan Cantor (Boston Children’s Hospital)

Role of the transcription factor RUNX1 downstream of activated SHP2 (PTPN11) in Juvenile Myelomonocytic Leukemia (JMML

13:50-14:10

Marshall Horwitz (University of Washington)

Restoring RUNX1 levels in FPD/AML by inhibiting its degradation

14:10-14:30

Leonard Zon (Boston Children’s Hospital)

Modeling clonal hematopoietic disorders using mosaic mutagenesis and color barcoding in zebrafish

14:30-15:00 Coffee
15:00-15:20

Benjamin Ebert (Dana Farber Cancer Institute)

Interaction of RUNX1 and the cohesion complex in megakaryocytic development and myeloid disease

15:20-15:40

Stephen Nimer (University of Miami)

Epigenetic modifying enzymes in FPD/AML

15:40-16:00

Guy Sauvageau (University of Montreal)

RUNX1 mutations that confer exquisite sensitivity to glucocorticoids

16:00-17:30

RUNX1 Research Program breakout session (Room 1-102 SCTR)

Chairs: Len Zon and Ravi Majeti

Clonal hematopoiesis in FPD/AML

16:10-17:30

Session 6. RUNX proteins in breast cancer

Chair: James Neil

16:10-16:30

James Neil (University of Glasgow)

Redundant roles of the RUNX gene family in oncogenesis and tumour suppression

16:30-16:50

Matthew Naylor (University of Sydney)

Novel role for CBFβ as a regulator of breast cancer phenotype, progression, and metastasis

16:50-17:10

Jane Lian (University of Vermont)

The protective role of Runx1 in breast cancer: EMT suppression, anti-tumor activity, and inhibition of stemness

17:10-19:00 Poster Session and Dinner (Jordon Medical Education Center, Atrium)
19:30-20:50

RUNX1 Research Program breakout session (Room 1-102 SCTR)

Chairs: Ben Ebert and Guy Sauvageau

Therapeutic approaches for FPD/AML

19:00-20:50

Session 7. Tissue specific functions of RUNX proteins

Chair: Gary Stein

19:00-19:20

Toshihisa Komori (Nagasaki University)

A role of Runx2 in the proliferation of osteoblast precursors

19:20-19:40

Ewan Cameron (University of Glasgow)

Runx1 deficiency protects against adverse cardiac remodeling following myocardial infarction

19:40-20:00 Gary Stein (University of Vermont)
20:00-20:30

Session 8. Speed Talks II

Chair: Peter Gergen

20:00-20:04

Xin Qin (Nagasaki University)

Elucidation of the functions of Runx2 in differentiated osteoblasts

20:04-20:08

Renaud Mevel (University of Manchester)

Investigation of the role of RUNX1 in normal prostate and prostate cancer

20:08-20:12

Yi-Jou Huang (University of California San Diego)

RUNX1 deficiency and SRSF2 mutation cooperate to promote myelodysplastic syndrome development 

20:12-20:16

Tao Zhen (National Human Genome Research Institute)

MDS-associated U2af1 mutation and Runx1 deficiency cooperate for leukemia development in a new mouse model

20:16-20:20

Amanda Davis (University of California San Diego)

A CRISPR RNA-binding protein screen reveals HNRNPA1 as a novel regulator of RUNX1 isoform generation

20:20-22:00 Poster Session (continued) and Cash Bar (Jordon Medical Education Center, Atrium)
Tuesday, November 14
8:00-9:00 Breakfast (SCTR Commons)
9:00-10:20

Session 9.  Heart, blood, neurons, hair, and sloppy-paired

Chair: Yoram Groner

9:00-9:20

J. Peter Gergen (SUNY Stony Brook)

Runt-dependent regulation of enhancer activity: dominant repression associated with promoter-proximal Pol II pausing

9:20-9:40

Lucas Waltzer (University of Toulouse)

Control of RUNX-induced repression of Notch signaling by the MLF/DnaJ-1 chaperone complex during fly hematopoiesis

9:40-10:00

Doina Tumbar (Cornell University)

Runx1 role in hair follicle stem cell lipid metabolism and blood vessel remodeling          

10:00-10:20

Yoram Groner (Weizmann Institute)

Runx3 regulates cell type specification during development of proprioception – the body’s “Sixth Sense”

10:20-10:50

Coffee Break (SCTR Commons)

10:50-12:10

Session 10: RUNX1 and leukemia, redux

Chair: Kinuko Mitani

10:50-11:10

Hironori Harada (Tokyo University of Pharmacy and Life Sciences)

Identification of critical mediators for bone marrow fibrosis in MDS using novel RUNX1-mutant/HMGA2-overexpression mouse model

11:10-11:30

Goro Sashida (Kumamoto University)          

RUNX1 super enhancer promotes the development of blastic plasmacytoid dendritic cell neoplasm

11:30-11:50

Thomas Milne (University of Oxford)

MLL-AF4 cooperates with RUNX1 in PRC2 axis

11:50-12:10

Kinuko Mitani (Dokkyo Medical University)

RUNX1-EVI induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice

12:10-13:00 Lunch (SCTR Commons)
13:30-18:00

Half-day tour of Longwood Gardens or the Barnes Museum

Sponsored by the RUNX1 Research Program

18:00-21:00

Walking Reception and Dinner at the Penn Museum

Sponsored by the RUNX1 Research Program

Wednesday, November 15
8:00-9:00 Breakfast (SCTR Commons)
9:00-10:20

Session 11. Back to breast cancer (mostly)

Chair: John Bushweller

9:00-9:20

Karen Blyth (Beaston Institute)

Deciphering the enigmatic role of RUNX1 in breast cancer

9:20-9:40

Zhe Li (Brigham and Women’s Hospital)

RUNX/CBFβ in mammary epithelial cell fate determination and breast cancer development

9:40-10:00

Jianqiang Wu (Cincinnati Children’s Hospital)

Runx1 and Runx3 cooperate to drive neurofibromagenesis

10:00-10:20

John Bushweller (University of Virginia)

Small molecule inhibitors of CBFβ/RUNX – utility for breast and ovarian cancer

10:20-10:50 Coffee Break (SCTR Commons)
10:50=11:10

Session 12.  Cellular functions of RUNX proteins

Chair: Suk-Chul Bae

11:10-11:30

Suk-Chul Bae (Chunbuk National University)

Runx3 plays a critical role in defense against cellular transformation through regulation of restriction-point decision

11:30-11:50

Yasuhiko Kamikubo (Kyoto University)

RUNX gene switch: RUNX cluster regulation

11:50-12:10

Olaf Heidenreich (Newcastle University)

Therapeutic targeting of RUNX1/ETO-mediated cell cycle progression

12:10-12:30

Stefano Stifani (McGill University)

Role of RUNX1 in glioblastoma development and recurrence

12:30-13:30 Lunch (SCTR Commons)
13:30 Depart